Fundraising Fox
Nocion Therapeutics
Watertown, US · Founded 2017 · Delaware corporation · 19 employees on LinkedIn · 6 known investors
Find your way into Nocion Therapeutics
Sign up to see every warm intro you have to Nocion Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nocion Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves. The company is advancing taplucainium inhalation powder, a first-in-class therapy in Phase 2b clinical development for refractory and unexplained chronic cough, with potential applications in pain, itch, and other conditions driven by neurogenic inflammation.
Founders & leadership
MF
MATTHEW FRANKELChief Medical OfficerHe brings over two decades of clinical development and medical affairs experience across major biopharmaceutical companies including Novartis (where he led the Immunology and Dermatology Medical Unit), Boehringer Ingelheim (Vice President of Clinical Development overseeing oncology, immunology, pulmonary, and CNS programs), and Chemomab (Chief Medical Officer). He holds an M.D. from UCLA, an MBA from Northwestern University's Kellogg School of Management, and a B.A. from Vassar College, and is board-certified in internal medicine.
PC
PETER COUROSSIExecutive
RB
RICHARD BATYCKYPresident and Chief Executive Officer
JE
JAMES ELLISExecutive
ML
MICHAEL LIPPSenior Vice President, Pharmaceutical Development2019–2023Michael Lipp holds a B.S. in Chemical Engineering from Cornell University and a Ph.D. in Chemical Engineering and Materials Science from UC Santa Barbara, with over two decades of experience in pharmaceutical development and drug delivery across preclinical through commercial stages. He previously held senior roles in pharmaceutical development at Nocion Therapeutics, Civitas Therapeutics (acquired by Acorda), Pulmatrix, and Alkermes, and began his career as a postdoctoral fellow and staff scientist at Advanced Inhalation Research focusing on pulmonary product development.
BM
BRIDGET M. COLESenior Vice President & Head of Chemistry2020–2023Bridget M. Cole is an Executive Officer at Nocion Therapeutics with a background in medicinal chemistry and drug discovery; she has directed discovery research and managed chemistry, manufacturing, controls, and preclinical development activities across multiple compounds from screening through Phase 2 clinical development.
BB
Bruce Bean, PhDFounder; Professor of Neurobiology, Harvard Medical School
BL
Bruce Levy, MDFounder; Chief of Pulmonology & Critical Care, Brigham and Women's Hospital
CW
Clifford Woolf, PhD, MB, BChFounder; Professor of Neurology and Neurobiology, Harvard Medical School
Board
VM
VIJAY MURTHYBoard director
JG
Investors · 6
Canaan Partners✓ confirmed by Nocion TherapeuticsStamford · $500K – $20Mvia Julie Grant · board
How we know: the company's own site · Canaan Partners's portfolio page · a partner's Signal profile · board seat on SEC Form D · businessinsider.com · Not right? Tell us
F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M
How we know: F-Prime Capital's portfolio page · businessinsider.com · Not right? Tell us
Lumira Ventureslisted by Lumira VenturesToronto · $1M – $10M
How we know: Lumira Ventures's portfolio page · Not right? Tell us
Mission Biocapitallisted by Mission BiocapitalSan Francisco · $500K
How we know: Mission Biocapital's portfolio page · press coverage · the VCSheet dataset · Not right? Tell us
Funding
SEC filings, press & company announcements$103.1M disclosed across 5 rounds · 2019–2025
- $27MSeries AApr 2019 · 2 sources
Canaan (lead), F-Prime Capital Partners (lead)
Source ↗
▶$23MraisedMar 2026 · 13 investors · PharmaceuticalsRule 506(b)
▶$23MraisedMar 2026 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- VIJAY MURTHYDirector
- JULIE GRANTDirector
- PINI ORBACHDirector
- ROSY HUDirector
- MATTHEW FRANKELExecutive Officer
- PETER COUROSSIExecutive Officer
- RICHARD BATYCKYExecutive Officer, Director
- JAMES ELLISExecutive Officer
- FREDDIE DEARDirector
- MICHAEL HIGGINSDirector
- Offering amount
- $23M
- Amount sold
- $23M
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$31.1MraisedMar 2024 · 13 investors · PharmaceuticalsRule 506(b)
▶$31.1MraisedMar 2024 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- JULIE GRANTDirector
- ROSY HUDirector
- BERNARD SILVERMANExecutive Officer
- RICHARD BATYCKYExecutive Officer, Director
- FREDDIE DEARDirector
- PINI ORBACHDirector
- PETER COUROSSIExecutive Officer
- MICHAEL HIGGINSDirector
- JAMES ELLISExecutive Officer
- VIJAY MURTHYDirector
- Offering amount
- $70M
- Amount sold
- $31.1M
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7MraisedAug 2022 · 10 investors · PharmaceuticalsRule 506(b)
▶$7MraisedAug 2022 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- JULIE PAPANEK GRANTDirector
- BRIDGET M. COLEExecutive Officer
- JESSICA ALSTONDirector
- MICHAEL HIGGINSDirector
- RICHARD BATYCKYExecutive Officer, Director
- MICHAEL LIPPExecutive Officer
- JONATHAN GARENExecutive Officer
- MEREDITH FISHERDirector
- JAMES ELLISExecutive Officer
- CHRISTOPHER SILBERExecutive Officer
- Offering amount
- $17M
- Amount sold
- $7M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedJan 2021 · 11 investors · PharmaceuticalsRule 506(b)
▶$15MraisedJan 2021 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- MICHAEL HIGGINSDirector
- JULIE PAPANEK GRANTDirector
- MEREDITH FISHERDirector
- JESSICA ALSTONDirector
- MICHAEL LIPPExecutive Officer
- JAMES ELLISExecutive Officer
- CHRISTOPHER SILBERExecutive Officer
- RICHARD BATYCKYExecutive Officer, Director
- BRIDGET M. COLEExecutive Officer
- Offering amount
- $25M
- Amount sold
- $15M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Maxion TherapeuticsMaxion Therapeutics develops protein and antibody therapeutics using its patented KnotBody technology, which fuses cysteine-rich miniproteins (Knottins) into antibody binding loops to target ion channels and GPCRs. It focuses on first-in-class and best-in-class treatments for diseases driven by ion channel and GPCR dysfunction, including pain, autoimmune and cardiovascular conditions.
Alexion PharmaceuticalsAlexion is a biopharmaceutical company focused on research and development of treatments for rare diseases, serving rare disease patients and their families worldwide.
Vividion TherapeuticsVividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins. The company operates across the full drug development spectrum from discovery to clinical development.
Eikon TherapeuticsPioneering a drug discovery method based on tracking the movement of individual proteins in living cells.
Companies working in the same space as Nocion Therapeutics.
In the news
Frequently asked questions
- What does Nocion Therapeutics do?
- Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves. The company is advancing taplucainium inhalation powder, a first-in-class therapy in Phase 2b clinical development for refractory and unexplained chronic cough, with potential applications in pain, itch, and other conditions driven by neurogenic inflammation.
- Who are Nocion Therapeutics's investors?
- Nocion Therapeutics's investors include Canaan Partners, F-Prime Capital, Lumira Ventures, Mission Biocapital, Monograph Capital Partners, OUP (Osage University Partners).
- How much funding has Nocion Therapeutics raised?
- Nocion Therapeutics has disclosed $103.1M raised across 5 rounds.
- Where is Nocion Therapeutics headquartered?
- Nocion Therapeutics is headquartered in Watertown, US.